Dr. Raed A. Dweik Lab


Raed A. Dweik, MD
Staff

Raed A. Dweik, MD
FACP, FRCP(C), FCCP, FCCM, FAHA

Staff, Department of Pathobiology / Lerner Research Institute
Director, Pulmonary Vascular Program, Pulmonary and Critical Care Medicine / Respiratory Institute
Professor of Medicine, The Cleveland Clinic Lerner College of Medicine of CWRU

The overall goal of our current studies is to understand lung physiology and pathology through the study of systemic and exhaled biomarkers . While our current focus is on the pathobiology of pulmonary hypertension, our work also covers lung physiology as well as the full spectrum of lung diseases that involve the airway (asthma), parenchyma (berylliosis-CBD), and the pulmonary circulation (pulmonary hypertension).

Research interest:

  • Pulmonary hypertension
  • Asthma
  • Beryllium-induced lung disease
  • Biologic markers of lung disease
  • Exhaled breath analysis
  • Role of nitric oxide (NO) in lung physiology and lung diseases

Annual Pulmonary Hypertension Symposium

To understand what to expect from the 2011 symposium please view past event brochures (2004 - 2010)


[ Click here to see more details ]

  • Metin Aytekin, Ph.D.
  • David Grove, Ph.D.
  • Gustavo Heresi, M.D.
  • Adriano Tonelli, M.D.
  • Frank Cikach, B.S.
  • Joseph Cody
  • Daniel Laskowski
  • Alquam Mashir
  • Jennie Newman
  • Liping Tian, B.S.
  • Serpil Erzurum, M.D.: Pathobiology, CCF
  • Suzy A. A. Comhair, Ph.D.: Pathobiology, CCF
  • Carol de la Motte, Ph.D.: Pathobiology, CCF
  • Suneel Apte, M.B.B.S., D. Phil.: Biomedical Engineering, CCF
  • Vincent Hascall, Ph.D.: Biomedical Engineering, CCF
  • Richard Krasuski, M.D.: Cardiology, CCF
  • W.H. Wilson Tang, M.D.: Cardiology, CCF
  • Alejandro Arrolioga, M.D.: Scott and White Clinic, Texas A and M University
  • Benjamin Gaston M.D.: University of Virginia
  • Gary Hunter, Ph.D.: National Aeronautics and Space Administration (NASA)
  • Cesare Saltini, M.D.: Dipartimento di Medicina Interna, Università di Roma "Tor Vergata", Roma, Italy
  • Prabir Dutta, Ph.D.: Ohio state University
  • CC Liu, Ph.D.: Case Western Reserve University
  • Michael Epton, BM BS BMedSci: Respiratory Services, Christchurch Hospital, Christchurch, New Zealand
  • Gerard Wysocki, Ph.D.: Princeton
    Physician Directory:
  • Raed A. Dweik, MD
    FACP, FRCP(C), FCCP, FCCM, FAHA
    Director, Pulmonary Vascular Program
    Dept. of Pulmonary, Allergy, and Critical Care Medicine
    Respiratory Institute
    Associate Professor of Medicine
    The Cleveland Clinic Lerner College of Medicine of CWRU
    dweikr@ccf.org
  • Serpil C. Erzurum, MD
    Chair, Department of Pathobiology
    Lerner Research Institute
    Professor of Medicine
    The Cleveland Clinic Lerner College of Medicine of CWRU
    erzurus@ccf.org
  • Omar A. Minai, MD
    Dept. of Pulmonary, Allergy, and Critical Care Medicine
    Respiratory Institute
    minaio@ccf.org
  • Constance A. Jennings, MD
    Dept. of Pulmonary, Allergy, and Critical Care Medicine
    Respiratory Institute
    jenninc@ccf.org
  • Joseph Parambil, MD
    Dept. of Pulmonary, Allergy, and Critical Care Medicine
    Respiratory Institute
    parambj@ccf.org
  • Gustavo Heresi, MD
    Dept. of Pulmonary, Allergy, and Critical Care Medicine
    Respiratory Institute
    heresig@ccf.org
  • Adriano Tonelli, MD
    Dept. of Pulmonary, Allergy, and Critical Care Medicine
    Respiratory Institute
    tonella@ccf.org

For further information or to schedule an appointment, please call or e-mail one of our advanced practice nurses:

  • Nancy D. Bair, R.N., M.S.N., C.N.S.
    216-445-9955,or
    1-800-CCF-CARE ext. 59955
    bairn@ccf.org
  • Svetlana Banjac, R.N., M.S.N., C.N.P.
    216-445-3636, or
    1-800-CCF-CARE ext. 53636
    banjacs@ccf.org

For information clinical trials, please contact:

  • BRCP 08-049 (Dweik)
    Sate of Ohio Third Frontier Program
    Breath Analysis: Targeted Sensor Development and Commercialization for Health Care Diagnostics
    State of Ohio Third Frontier Research Commercialization Program (RCP)
  • NIH: SBIR PA-09-080 – R43/R44 (Dweik, at CCF)
    S-nitrosothiol Analyzer for the Clinical Diagnosis of Cardiovascular Disease AHA 0826095 (Aytekin)
    Hyaluronan in Pulmonary Arterial Hypertension
    American Heart Association (AHA)-Pulmonary Hypertension Association (PHA)
  • Gilead Scholars Program (Heresi)
    Myeloperoxidase (MPO) in Pulmonary Hypertension
    Gilead Sciences
  • 5PO1 HL081064-02 (Erzurum)
    NIH
    The Pathobiology of Asthma
    The major goal of this core is to provide the clinical expertise and organization necessary to accomplish the studies involving human subjects that are proposed in the projects within the PPG. The core will be responsible for subject characterization through clinical data acquisition and subject follow-up.
    Role: Principal Investigator / Core Director of Clinical Core (Core B) FDA-IND holder: Whole Lung and Segmental Allergen Challenge in Asthma
  • BREath Analysis and Testing in Human Health (BREATH) study
    Cleveland Clinic
    Contact: Kelly Paschke: 216-445-4365
  • Pulmonary Hypertension Registry.
    Cleveland Clinic
    Contact Jennie Newman: 216-444-7950
  • Pulmonary Hypertension Universal TissUe REpository (PHUTURE) project.
    Cleveland Clinic
    Contact Jennie Newman: 216-444-7950
  • Novartis: QTI571A2301
    A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study (IMPRES)
    Contact Katie Zak: 216-636-2421 or Mary McAllister: 216-445-9557
  • Gilead Sciences: GS-US-235-0101
    A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension.
    Role: Cleveland Clinic Site Principal Investigator
    Contact Katie Zak: 216-636-2421 0r Mary McAllister: 216-445-9557
  • Cotherix, Actelion
    Registry to EValuate Early And Long-term PAH Disease Management (REVEAL)
    Contact Jennie Newman: 216-444-7950